Raymond James Financial Inc. Purchases Shares of 50,906 NeoGenomics, Inc. (NASDAQ:NEO)

Raymond James Financial Inc. acquired a new stake in shares of NeoGenomics, Inc. (NASDAQ:NEO - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 50,906 shares of the medical research company's stock, valued at approximately $839,000.

A number of other hedge funds also recently bought and sold shares of NEO. FMR LLC grew its position in shares of NeoGenomics by 7.6% in the third quarter. FMR LLC now owns 13,255 shares of the medical research company's stock valued at $196,000 after purchasing an additional 931 shares in the last quarter. Blue Trust Inc. boosted its stake in NeoGenomics by 33.2% during the fourth quarter. Blue Trust Inc. now owns 4,421 shares of the medical research company's stock worth $73,000 after buying an additional 1,103 shares during the last quarter. Versant Capital Management Inc grew its holdings in NeoGenomics by 174.9% in the 4th quarter. Versant Capital Management Inc now owns 1,795 shares of the medical research company's stock valued at $30,000 after buying an additional 1,142 shares in the last quarter. SBI Securities Co. Ltd. acquired a new stake in shares of NeoGenomics in the 4th quarter worth $26,000. Finally, KBC Group NV raised its holdings in shares of NeoGenomics by 44.7% during the 4th quarter. KBC Group NV now owns 6,557 shares of the medical research company's stock worth $108,000 after acquiring an additional 2,027 shares during the period. Institutional investors and hedge funds own 98.50% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the stock. Piper Sandler dropped their price objective on shares of NeoGenomics from $21.00 to $18.00 and set an "overweight" rating for the company in a report on Wednesday, February 26th. Benchmark downgraded shares of NeoGenomics from a "buy" rating to a "hold" rating in a report on Monday, January 13th. Bank of America reduced their price target on shares of NeoGenomics from $19.00 to $16.00 and set a "neutral" rating on the stock in a research report on Wednesday, February 19th. The Goldman Sachs Group lowered their price objective on NeoGenomics from $20.00 to $18.00 and set a "buy" rating for the company in a research report on Tuesday, January 28th. Finally, Needham & Company LLC reduced their target price on NeoGenomics from $19.00 to $18.00 and set a "buy" rating on the stock in a research report on Wednesday, February 19th. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $19.60.

Remove Ads

NeoGenomics Trading Up 11.2 %

Shares of NEO traded up $0.92 during midday trading on Wednesday, hitting $9.12. 3,219,702 shares of the stock were exchanged, compared to its average volume of 922,959. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.91 and a current ratio of 1.98. The firm has a market cap of $1.17 billion, a P/E ratio of -14.71 and a beta of 1.41. NeoGenomics, Inc. has a 52-week low of $8.15 and a 52-week high of $19.12. The stock has a fifty day simple moving average of $10.78 and a 200 day simple moving average of $13.86.

NeoGenomics (NASDAQ:NEO - Get Free Report) last released its earnings results on Tuesday, February 18th. The medical research company reported ($0.02) earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.05). The firm had revenue of $172.00 million during the quarter, compared to analyst estimates of $173.40 million. NeoGenomics had a negative net margin of 11.92% and a negative return on equity of 2.10%. On average, research analysts anticipate that NeoGenomics, Inc. will post -0.2 EPS for the current fiscal year.

NeoGenomics Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.